Elicio Therapeutics (ELTX) Debt Ratio (2020 - 2026)

Elicio Therapeutics' (ELTX) quarterly Debt Ratio came in at 0.42 in Q1 2026, up 14.81% on a QoQ basis from 0.36 in Q4 2025.

Elicio Therapeutics (ELTX) Debt Ratio (2020 - 2026) Analysis & Trends

Elicio Therapeutics (ELTX) has 4 years of Debt Ratio data on file, last reported at 0.42 in Q1 2026.

Quarterly Debt Ratio changed N/A year-over-year to 0.42 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.42 (changed N/A YoY) and the FY2025 annual result came in at 0.36, down 48.84% from the prior year.
Debt Ratio improved to 0.42 in Q1 2026, from 0.36 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.71 in Q4 2024 to a low of 0.32 in Q2 2025.
A 3-year average of 0.43 and a median of 0.36 in 2025 frame the typical range for Debt Ratio.
The widest YoY moves for Debt Ratio: up 48.84% in 2025, down 48.84% in 2025.
Tracing ELTX's Debt Ratio over 3 years: stood at 0.71 in 2024, then sank by 48.84% to 0.36 in 2025, then increased by 14.81% to 0.42 in 2026.
The last three Debt Ratio figures came in at 0.42 (Q1 2026), 0.36 (Q4 2025), and 0.34 (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	0.05
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	0.26
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.47
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	0.03
10	Elicio Therapeutics	59.08 Mn	35.58 Mn	-	0.30

Download Data